中国血液净化

中国血液净化 ›› 2022, Vol. 21 ›› Issue (11): 827-830.doi: 10.3969/j.issn.1671-4091.2022.11.009

• 综述 • 上一篇    下一篇

甲磺酸萘莫司他抗凝在连续性肾脏替代治疗的应用进展

孙献坤   王 芳   陈志文   张 凌   

  1. 610041  成都，1四川大学华西护理学院 
    610041  成都，2四川大学华西医院肾脏内科
  • 收稿日期:2022-04-18 修回日期:2022-05-16 出版日期:2022-11-11 发布日期:2022-11-12
  • 通讯作者: 陈志文 E-mail:kiyuhot@163.com
  • 基金资助:
    四川省科技计划项目重点研发项目(2020YFG0105)

Progresses in the application of nafamostat mesylate for anticoagulation during continuous renal replacement therapy 

SUN Xian-kun   WANG Fang, CHEN Zhi-wen, ZHANG Ling   

  1. West China School of Nursing, Sichuan University, Chengdu 610041, China;  2Department of Nephrology, West China Hospital, Sichuan University, Chengdu 610041, China
  • Received:2022-04-18 Revised:2022-05-16 Online:2022-11-11 Published:2022-11-12
  • Contact: 610041 成都，四川大学华西医院肾脏内科 E-mail:kiyuhot@163.com

PDF

397

摘要： 现有抗凝剂可能存在相应的使用禁忌和副作用，以致于无抗凝连续性肾脏替代治疗(continuous renal replacement therapy，CRRT)仍很常见。甲磺酸萘莫司他(nafamostatmesylate，NM)半衰期短，能降低危重患者血液净化时出血风险，在韩国和日本被广泛应用于体外循环回路抗凝。然而， NM抗凝的标准处方、有效剂量、监测方法等尚未形成共识。笔者综述CRRT患者采用NM抗凝的作用机制、使用方法、抗凝效果、局限性等，为后续研究提供参考。

关键词: 连续性肾脏替代治疗, 甲磺酸萘莫司他

Abstract: The anticoagulants currently used may have contraindications and side effects, therefore continuous renal replacement therapy without anticoagulation is still common. Nafamostat mesylate has a short half-life, which may help critically ill patients avoid bleeding during blood purification. In Korea and Japan, Nafamostat mesylate is frequently utilized for anticoagulation in extracorporeal circulation line. However, there are no consensuses about the fundamental anticoagulant prescription, effective dose and monitoring strategy of the drug. Here we review the anticoagulation mechanism of nafamostat mesylate in patients on continuous renal replacement therapy, method of use, anticoagulation effect and limitations, so as to give a reference for future studies.

Key words: Continuous renal replacement therapy, Nafamostat mesylate

中图分类号: